Skip to main content Skip to search Skip to main navigation

PANGEA XV: Worldwide Campaign against Falsified and Illegally Imported Medicinal Products

From 23 to 30 June 2022, Interpol conducted its 15th globally coordinated operation PANGEA against the illegal online trade of medicines. From fake COVID-19 tests to doping substances or narcotics, the range of illegal shipments was broad.

This year, 94 countries were involved in the operation. A total of more than 3 million units were seized worldwide, including more than 7,800 illegal and counterfeit medicines and medical products. The found counterfeit medicines were mostly produced in Asian countries with counterfeit erectile stimulants originating in India.

During the week, law enforcement

  • Investigated more than 4,000 web links, mainly from social media platforms and messaging apps
  • Shut down or removed more than 4,000 web links containing adverts for illicit products
  • Inspected nearly 3,000 packages and 280 postal hubs at airports, borders and mail distribution or cargo mail centres
  • Opened more than 600 new investigations and issued more than 200 search warrants

While results are still coming in from countries, enforcement actions have already disrupted the activities of at least 36 organized crime groups.

About 40 % of all products seized were counterfeit or unapproved erectile stimulants. Law enforcement agencies in Australia, Argentina, Malaysia, and the United States also seized more than 317,000 unapproved COVID-19 test kits. The seizures in the US alone have an estimated value of nearly USD 3 million.

If you are interested in more information on the global action please click here.


Source:

Interpol: PANGEA XV

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

EMA: Q&A Paper on Measures to Prevent Microbial Contamination of Non-Sterile Medicinal Products

The EMA has published a new Q&A paper on technical and organisational measures to prevent microbial contamination of non-sterile medicinal products.
Read more
When APS Fail and First Air is at Risk

When APS Fail and First Air is at Risk

At the PDA Good Aseptic Manufacturing Conference 2026, Alberto Gonzales (Takeda) discussed challenges and practical solutions related to aseptic process simulations (APS). Anna Campanella (Takeda) and Hussein Bachir (Franz Ziel) explored how first air protection in aseptic processing can be compromised by equipment design, glove interventions, and operator activities.
Read more
Why is import authorisation necessary for medicinal products entering the EU?

Why is import authorisation necessary for medicinal products entering the EU?

Read more
FDA: Updated Compliance Program for Preapproval Inspections

FDA: Updated Compliance Program for Preapproval Inspections

The FDA has revised its Compliance Program 7346.832, “Preapproval Inspections”. The updated program describes the planning, conduct and evaluation of preapproval inspections (PAIs) for New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs).
Read more
EMA: Revised Q&A MRA EU-USA

EMA: Revised Q&A MRA EU-USA

The EMA has updated its Questions and Answers on the EU-US Mutual Recognition Agreement (MRA). The update follows the completion of the FDA's assessment of all EU authorities responsible for GMP inspections of veterinary medicinal products on 29 May 2026.
Read more
WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO: Draft on Regulatory Ovesight of Disposal of Medical Products

WHO published a draft consultation document on regulatory oversight of disposal of medical products throughout the lifecycle.
Read more
Previous
Next